Observational studyPloS one2014
Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period.
Observational study in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Hepatitis C prevalence in incarcerated settings between 2013-2021: a systematic review and meta-analysis.BMC public health · 2022Pooled it
- The global and regional prevalence of hepatitis C and B co-infections among prisoners living with HIV: a systematic review and meta-analysis.Infectious diseases of poverty · 2021Pooled it
- The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons: A Systematic Review.Infectious disease clinics of North America · 2020Pooled it
- Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019Pooled it
- Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.BMC public health · 2014Trial
- Regional epidemiological study of hepatitis B, hepatitis C, and human immunodeficiency virus among prisoners.BMC public health · 2025Article
- How to eliminate hepatitis C between people who inject drugs in community services and prisons in Catalonia.Harm reduction journal · 2025Review
- Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.Journal of viral hepatitis · 2024Article
- New hepatitis C virus infection, re-infection and associated risk behaviour in male Irish prisoners: a cohort study, 2019.Archives of public health = Archives belges de sante publique · 2021Article
- Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.The lancet. Gastroenterology & hepatology · 2021Review
- Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky.The International journal on drug policy · 2021Article
- Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners.Harm reduction journal · 2019Observational
- Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection.Revista espanola de sanidad penitenciaria · 2017Review
- Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.Addiction (Abingdon, England) · 2017Article
- Co-infections and transmission networks of HCV, HIV-1 and HPgV among people who inject drugs.Scientific reports · 2015Article
- Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland.Hepatitis monthly · 2015Article
- Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain.Revista espanola de sanidad penitenciariaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo estimate the incidence of Hepatitis C virus (HCV) and the predictive factors through repeated routine laboratory analyses.
methodsAn observational cohort study was carried out in Quatre Camins Prison, Barcelona. The study included subjects with an initial negative HCV result and routine laboratory analyses containing HCV serology from 1992 to 2011. The incidence of infection was calculated for the study population and for sub-groups by 100 person-years of follow-up (100 py). The predictive factors were determined through Kaplan-Meier curves and a Cox regression. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated.
resultsA total of 2,377 prisoners were included with a median follow-up time of 1,540.9 days per patient. Among the total population, 117 HCV seroconversions were detected (incidence of 1.17/100 py). The incidence was higher between 1992 and 1995 (2.57/100 py), among cases with HIV co-infection (8.34/100 py) and among intravenous drug users (IDU) without methadone treatment (MT) during follow-up (6.66/100 py). The incidence rate of HCV seroconversion among cases with a history of IDU and current MT was 1.35/100 py, which is close to that of the total study population. The following variables had a positive predictive value for HCV infection: IDU (p<0.001; HR = 7,30; CI: 4.83-11.04), Spanish ethnicity (p = 0.009; HR = 2,03; CI: 1.93-3.44) and HIV infection (p = 0.015; HR = 1.97; CI: 1.14-3.39).
conclusionThe incidence of HCV infection among prisoners was higher during the first part of the study and among IDU during the entire study period. Preventative programs should be directed toward this sub-group of the prison population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.